Italy seeks 1.2 bn euros in anti-trust damages from Roche, Novartis

Italy's health ministry is seeking 1.2 billion euros ($1.6 million) in compensation from Swiss pharma giants Novartis and Roche for the manipulation of sales of a cheap drug used to treat eye problems, Italian media reported Wednesday.

The ministry's move came after Italy's antitrust body fined the two firms 182.5 million euros over their "illicit deal to prevent the use of a very cheap drug, Avastin, in treating" sight problems.

The antitrust body said the two pharma giants had colluded with the aim of boosting the sales of a more expensive product, Lucentis. It also claimed that they steered health services and doctors away from Avastin by describing it as more dangerous.

Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as .

Novartis has rejected the anti-competition accusations and has said it would appeal against the fine.

add to favorites email to friend print save as pdf

Related Stories

Novartis tries to make UK hospitals use $1000 drug

Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

FDA warns of another compounding pharmacy recall

Mar 20, 2013

(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Japan prosecutors raid Novartis over drug ad scandal

Feb 19, 2014

Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments